Publicaciones (120) Publicaciones en las que ha participado algún/a investigador/a

2022

  1. 11C-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to 18F-FDG PET/CT and Prognostic Value

    International Journal of Molecular Sciences, Vol. 23, Núm. 17

  2. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

    The Lancet Oncology, Vol. 23, Núm. 7, pp. e334-e347

  3. 3D printed bioresorbable scaffolds for articular cartilage tissue engineering: A comparative study between neat polycaprolactone (PCL) and poly(lactide-b-ethylene glycol) (PLA-PEG) block copolymer

    Biomedical Materials (Bristol), Vol. 17, Núm. 4

  4. A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research

  5. A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα and IL-1β

    Cancer Discovery, Vol. 12, Núm. 9, pp. 2140-2157

  6. A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells

    Cell Metabolism, Vol. 34, Núm. 6, pp. 857-873.e9

  7. A human IgE bispecific antibody shows potent cytotoxic capacity mediated by monocytes

    Journal of Biological Chemistry, Vol. 298, Núm. 8

  8. A network-based approach to integrate nutrient microenvironment in the prediction of synthetic lethality in cancer metabolism

    PLoS Computational Biology, Vol. 18, Núm. 3

  9. A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression

    Molecular Therapy - Nucleic Acids, Vol. 29, pp. 413-425

  10. A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results

    Leukemia and Lymphoma, Vol. 63, Núm. 1, pp. 93-100

  11. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

  12. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

    Transplantation and Cellular Therapy, Vol. 28, Núm. 6, pp. 284-293

  13. Advances in mRNA-based drug discovery in cancer immunotherapy

    Expert Opinion on Drug Discovery, Vol. 17, Núm. 1, pp. 41-53

  14. An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis

    Leukemia, Vol. 36, Núm. 8, pp. 2076-2085

  15. Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple Myeloma

    Cancers, Vol. 14, Núm. 21

  16. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

    Nature Medicine

  17. BOSO: A novel feature selection algorithm for linear regression with high-dimensional data

    PLoS Computational Biology, Vol. 18, Núm. 5

  18. Biological Characterization and Clinical Relevance of Circulating Tumor Cells: Opening the Pandora’s Box of Multiple Myeloma

    Cancers, Vol. 14, Núm. 6

  19. C/EBPβ regulates lipid metabolism and Pparg isoform 2 expression in alveolar macrophages

    Science Immunology, Vol. 7, Núm. 75

  20. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

    Science Advances, Vol. 8, Núm. 39